Imipenem
File:Imipenem.svg | |
Clinical data | |
---|---|
Pregnancy category |
|
Routes of administration | IM, IV |
ATC code | |
Pharmacokinetic data | |
Metabolism | Renal |
Elimination half-life | 60 minutes |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
E number | {{#property:P628}} |
ECHA InfoCard | {{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value). |
Chemical and physical data | |
Formula | C12H17N3O4S |
Molar mass | 299.347 g/mol |
WikiDoc Resources for Imipenem |
Articles |
---|
Most recent articles on Imipenem |
Media |
Evidence Based Medicine |
Clinical Trials |
Ongoing Trials on Imipenem at Clinical Trials.gov Clinical Trials on Imipenem at Google
|
Guidelines / Policies / Govt |
US National Guidelines Clearinghouse on Imipenem
|
Books |
News |
Commentary |
Definitions |
Patient Resources / Community |
Directions to Hospitals Treating Imipenem Risk calculators and risk factors for Imipenem
|
Healthcare Provider Resources |
Causes & Risk Factors for Imipenem |
Continuing Medical Education (CME) |
International |
|
Business |
Experimental / Informatics |
Imipenem is an intravenous beta-lactam antibiotic developed in 1985.
Imipenem belongs to the subgroup of carbapenems. It is derived from a compound called thienamycin, which is produced by the bacteria Streptomyces cattleya. Imipenem has a broad spectrum of activity against aerobic and anaerobic Gram positive as well as Gram negative bacteria. It is particularly important for its activity against Pseudomonas aeruginosa and the Enterococcus species. It is not active against methicillin-resistant Staphylococcus aureus, however. Imipenem and other drugs in the carbapenem class are commonly referred to as "magic bullets." Their use is typically restricted in order to avoid widespread bacterial resistance.
Method of action
Imipenem acts as an antimicrobial through inhibiting cell wall synthesis of various gram-positive and gram-negative bacteria. It remains very stable in the presence of beta-lactamase (both penicillinase and cephalosporinase) produced by some bacteria, and is a strong inhibitor of beta-lactamases from some gram-negative bacteria that are resistant to most beta-lactam antibiotics.
Co-administration with cilastatin
Imipenem is rapidly degraded by the renal enzyme dehydropeptidase when administered alone, and is always co-administered with cilastatin to prevent this inactivation.
Adverse effects
Common adverse drug reactions are nausea and vomiting. People who are allergic to penicillin and other beta-lactam antibiotics should not take imipenem. Imipenem can also cause seizures.
References
^ Clissold SP, Todd PA, Campoli Richards DM. Imipenem/Cilastatin: A reivew of its anti-bacterial activity, pharmacokinetic properties and therapeutic efficacy. Drugs 1987; 33: 183-241.
See also
- Pages with script errors
- Pages with broken file links
- E number from Wikidata
- ECHA InfoCard ID from Wikidata
- Chemical articles with unknown parameter in Infobox drug
- Articles without EBI source
- Chemical pages without ChemSpiderID
- Chemical pages without DrugBank identifier
- Articles without KEGG source
- Articles without InChI source
- Articles without UNII source
- Drugs with no legal status
- Articles containing unverified chemical infoboxes
- Carbapenem antibiotics